LexaGene unveiled the LX2 prototype design to a veterinary diagnostics audience on October 20th, 2018 at the AAVLD Annual Meeting in Kansas City. LX2 Prototype design; Unveiling at Booth 203 by CEO Dr. Jack Regan; Veterinary diagnosticians engaging with LX2 technology.
See how rapid, point-of-care molecular diagnostics could have improved patient outcome. Read the story of how Nancy the Dachshund did not receive the correct treatment due to the lag-time to receive lab results, and how LexaGene’s LX6 could have prevented this scenario.
LexaGene describes the technology behind our fully automated, open-access pathogen detection device, the LX Analyzer.